Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT06141460
PHASE1/PHASE2

Safety and Efficacy of RRG001 Gene Therapy in Subjects With Neovascular Age-related Macular Degeneration (nAMD)

Sponsor: Shanghai Refreshgene Technology Co., Ltd.

View on ClinicalTrials.gov

Summary

A Phase I/IIa, Dose-escalation and Dose-expansion Study to Evaluate the Safety and Efficacy of Single Subretinal Injection of RRG001 in Subjects With Neovascular Age-related Macular Degeneration

Official title: A Phase I/IIa, Dose-escalation and Dose-extension Study to Evaluate the Safety and Efficacy of Single Subretinal Injection of RRG001 in Subjects With Neovascular Age-related Macular Degeneration

Key Details

Gender

All

Age Range

50 Years - Any

Study Type

INTERVENTIONAL

Enrollment

48

Start Date

2023-12-12

Completion Date

2030-12-31

Last Updated

2024-11-14

Healthy Volunteers

No

Interventions

DRUG

RRG001

Administered via Subretinal injection. Dosage form: injection solution.

Locations (1)

Tianjin Medical University Eye Hospital

Tianjin, Tianjin Municipality, China